CLXPFCYBIN INC.

NYSE cybin.com


$ 0.25 $ -0.02 (-5.66 %)    

Tuesday, 02-Jul-2024 09:44:01 EDT
QQQ $ 482.06 $ 2.17 (0.45 %)
DIA $ 391.07 $ 0.23 (0.06 %)
SPY $ 544.85 $ 1.11 (0.2 %)
TLT $ 90.62 $ -0.05 (-0.06 %)
GLD $ 215.83 $ 0.56 (0.26 %)
$ 0.265
$ 0.26
$ 0.00 x 0
$ 0.00 x 0
$ 0.25 - $ 0.26
$ 0.25 - $ 0.74
4,350,796
na
201.41M
$ 0.48
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 what-do-you-really-know-about-psychedelics-and-psychedelics-stocks

According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use.

 cybin-becomes-first-psychedelics-company-on-the-nyse-ceo-explains-everything-you-need-to-know

Cybin (NYSE: CYBN), a biotech company in the psychedelics space, began listing its stock on the New York Stock Exchange on Thur...

 psychedelics-research-fyi-every-clinical-trial-underway-right-now-involving-public-and-private-companies

This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Psilocybin Alpha. In jus...

 psyched-field-trip-uplists-to-nasdaq-mindmed-to-study-dmt-atai-launches-new-subsidiary-aocs-psychedelics-amendment-rejected

Last week in Psychedelics:

Core News & Articles

HC Wainwright & Co. analyst Patrick Trucchio initiates coverage on Cybin (OTC:CLXPF) with a Buy rating and announces Pri...

 psyched-cybin-and-field-trip-head-to-wall-street-aoc-pushes-for-federal-psychedelics-research-off-label-ketamine-covered-by-insurance-in-canada

Cybin Inc.

 field-trip-health-heads-to-the-nasdaq-as-wall-street-opens-up-to-psychedelics-renaissance

Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector.

 cybin-lands-conditional-approval-to-become-the-first-psychedelics-company-on-the-nyse

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF), a biotech company in the psychedelics space, announced on Thursday a conditional approva...

 psyched-numinus-mindmed-cybin-reach-milestones-harvard-to-study-psychedelics-law-michael-pollan-dives-into-mescaline

Michael Pollan’s New Book Takes A Deep Dive Into Mescaline – Will This Be A Turning Point For The Recognition And Study of Mesc...

Core News & Articles

Aegis Capital analyst Nathan Weinstein initiates coverage on Cybin (OTC:CLXPF) with a Buy rating and announces Price Target ...

 psychedelics-research-fyi-every-clinical-trial-underway-right-now-involving-public-and-private-companies

This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Psilocybin Alpha. In jus...

 psyched-gh-research-debuts-on-nasdaq-compass-reaches-psilocybin-research-milestone-maxim-gives-buy-rating-to-10-psychedelics-companies

Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential of 5-MeO-DMT f...

 maxim-group-gives-buy-rating-to-10-psychedelic-stocks-compass-mindmed-cybin-field-trip-and-more

Institutional analysts are taking a liking to the industry of medicinal psychedelics. This week, investment bank Maxim Group in...

 cybin-inc-biotech-co-reports-51-million-in-cash-as-stifel-ups-price-target-to-12

Psychedelics companies continue to receive welcoming signs from Wall Street. As more companies commence their Nasdaq listings, ...

 psyched-atai-life-sciences-hits-nasdaq-canada-to-fund-ketamine-trials-mydecine-launches-ai-drug-discovery-platform

Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq debut on Friday.

 psyched-atais-214m-ipo-mindmed-ceo-resigns-field-trip-applies-to-nasdaq-cybin-and-novamind-target-frontline-health-workers

Atai Launches $214 Million Nasdaq IPO Offering Psychedelics biotech platform Atai life Sciences has announced an initial publi...

 cybin-to-co-sponsor-clinical-trial-testing-psilocybin-in-frontline-health-workers-with-covid-related-distress

Psychedelics and biotech company Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) is co-sponsoring a new clinical trial that will test the...

 what-do-you-really-know-about-psychedelics-and-psychedelics-stocks

According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use.